Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 3/20 | 0.31 |
| ▸ | FLT3 | P36888 | 3/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905252 | 1.00 | EDNRB (0.34) | EDNRBEDNRAPDK2PROKR1QRFPR | |
| SCHEMBL3806284 | 0.80 | EDNRB (0.33) | EDNRBEDNRAPROKR1 | |
| SCHEMBL3060798 | 0.74 | HCAR3 (0.40) | PDK2CDK4FLT3 | |
| SCHEMBL3057601 | 0.74 | HCAR3 (0.40) | PDK2CDK4FLT3 | |
| SCHEMBL2905250 | 0.74 | HCAR3 (0.40) | PDK2CDK4FLT3 | |
| SCHEMBL2110258 | 0.72 | RIPK1 (0.33) | EDNRBEDNRA | |
| SCHEMBL4198319 | 0.71 | MEN1 (0.34) | PROKR1ACACB | |
| SCHEMBL4214604 | 0.71 | HSP90AA1 (0.33) | PROKR1CDK4 | |
| SCHEMBL2913101 | 0.70 | KDM4E (0.41) | — | |
| SCHEMBL2910573 | 0.70 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | EDNRB 181/4885EDNRA 142/4885PDK2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.